SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Sick Visit — Jesse Owens

PatientJesse Owens
Date of birth1960-09-12
IdentifiersMRN HR-ML042-SYN; SSN (made up) 000-42-8319
Document date2026-07-06
AuthorClarence Whitfield-Arroyo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Runny nose, sore throat and a dry cough for three days, twelve days after the second cycle. [S]

History of Present Illness

Mr. Owens called the oncology line on day 13 of his second cycle of nivolumab with carboplatin and pemetrexed and was seen the same day, as his warning list asks for any new cough. Three days ago he developed a runny nose and a scratchy throat, and since yesterday a dry cough, worst at night. Several children at a youth club where he spoke last week had colds. His highest temperature at home was 37.8 °C last night. He has no breathlessness: he walked his usual 3 km this morning, a little slower. He has no chest pain, no blood in his sputum, no diarrhea and no rash. He has not smoked since the first cycle and has had no urge to with the cough. He takes varenicline twice daily and had his dexamethasone only around the infusion. He is worried that the cough means the immunotherapy is affecting his lungs. [S]

ElementDetail
OnsetThree days ago, after a youth club visit where several children had colds
SeverityDry cough, worse at night; no breathlessness at rest or on his morning walk
ContextDay 13 of cycle 2 of nivolumab with carboplatin and pemetrexed
Associated signs and symptomsRunny nose, sore throat, temperature up to 37.8 °C; no chest pain, hemoptysis, diarrhea or rash
Modifying factorsHoney and warm drinks help the throat

Review of Systems

SystemResultFinding
ConstitutionalPositiveLow-grade temperature to 37.8 °C; tired; no rigors
Ears, nose, mouth, and throatPositiveRunny nose and sore throat; no mouth sores
RespiratoryPositiveDry cough for a day; no breathlessness, wheeze or hemoptysis
CardiovascularNegativeNo chest pain, palpitations or leg swelling
GastrointestinalNegativeNo diarrhea or abdominal pain
IntegumentaryNegativeNo rash or itching

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 80.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7Oral route2026-05-26 to 2026-06-01completedS
Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse1 mg twice daily after foodOral route2026-06-02activeS
Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial)Day 1 every 21 days for three cyclesIntravenous route2026-06-03 to 2026-07-15completedS
Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cyclesDay 1 every 21 days for three cyclesIntravenous route2026-06-03 to 2026-07-15completedS
Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cyclesDay 1 every 21 days for three cyclesIntravenous route2026-06-03 to 2026-07-15completedS
Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the lastOne tablet dailyOral route2026-05-26 to 2026-08-05completedS
Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed)1000 mcg once; a second dose was not due before pemetrexed endedIntramuscular route2026-05-26 to 2026-05-26completedS
Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose4 mg twice daily for three days around each cycleOral route2026-06-02 to 2026-07-16completedS
Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy8 mg every 8 hours as neededOral route2026-06-03 to 2026-07-31completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-06Body height178cmS
2026-07-06Body weight75.6kgS
2026-07-06Body mass index (BMI) [Ratio]23.9kg/m2S
2026-07-06Systolic blood pressure128mm[Hg]S
2026-07-06Diastolic blood pressure78mm[Hg]S
2026-07-06Heart rate84/minS
2026-07-06Respiratory rate16/minS
2026-07-06Body temperature37.6CelS
2026-07-06Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-06Hemoglobin [Mass/volume] in Blood13.1g/dL13.5-17.5 g/dLLowS
2026-07-06Leukocytes [#/volume] in Blood by Automated count5.410*3/uL4-11 10*3/uLNormalS
2026-07-06Neutrophils [#/volume] in Blood by Automated count3.210*3/uL1.5-7.7 10*3/uLNormalS
2026-07-06Platelets [#/volume] in Blood by Automated count17610*3/uL150-400 10*3/uLNormalS

Physical Exam

Vital signs recorded on 2026-07-06; see the Vital Signs section. [S]

SystemFinding
GeneralComfortable, talking in full sentences; temperature 37.6 °C
Vital signsOxygen saturation 96 percent at rest, as at his earlier visits, and 95 percent after a 6-minute corridor walk; respiratory rate 16
Head, eyes, ears, nose, and throatRed throat without exudate; clear nasal discharge; no mouth ulcers
NeckNo tender or enlarged lymph nodes
RespiratoryClear to auscultation throughout; no crackles or wheeze
SkinNo rash

Problems

ProblemClinical statusVerificationCodeProvenance
Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review bookedresolvedconfirmed R91.1S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit.
Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alterationactiveconfirmed C34.12S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable.
Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicineactiveconfirmed F17.210S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission.
Acute viral upper respiratory infection (rhinovirus on a respiratory panel) on day 13 of cycle 2 of chemoimmunotherapy: runny nose, sore throat and a dry cough for three days, no hypoxia, clear chest X-ray; immune-related pneumonitis and pneumonia excluded; resolvedactiveconfirmed J06.9S — Synthetic intercurrent illness; not a historical claim.

Assessment and Plan

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021)

Follow-up: Nurse telephone call in two days. Cycle 3 in nine days. Call the oncology line for any warning sign. Next scheduled visit 2026-08-05: after three cycles: restaging CT, decision for lobectomy, thyroid result and surgical preparation. [S]